Bioengineered nisin derivative m17q has enhanced activity against staphylococcus epidermidis

dc.contributor.authorTwomey, Ellenen
dc.contributor.authorHill, Colinen
dc.contributor.authorField, Desen
dc.contributor.authorBegley, Máireen
dc.contributor.funderCork Institute of Technologyen
dc.date.accessioned2024-03-27T12:07:45Z
dc.date.available2024-03-27T12:07:45Z
dc.date.issued2020en
dc.description.abstractStaphylococcus epidermidis is frequently implicated in medical device-related infections. As a result of this, novel approaches for control of this opportunistic pathogen are required. We examined the ability of the natural peptide nisin A, produced by Lactococcus lactis, to inhibit S. epidermidis. In addition, a bank of 29 rationally selected bioengineered L. lactis strains were examined with the aim of identifying a nisin derivative with enhanced antimicrobial activity. Agar-based deferred antagonism assays revealed that wild type nisin A inhibited all 18 S. epidermidis strains tested. Larger zones of inhibition than those obtained from the nisin A producing L. lactis strain were observed for each derivative producer against at least one S. epidermidis strain tested. Six derivative producing strains, (VGA, VGT, SGK, M21A, M17Q, AAA), gave larger zones against all 18 strains compared to the wildtype producing strain. The enhanced bioactivity of M17Q was confirmed using well diffusion, minimum inhibitory concentration (MIC) and a broth-based survival assays. Biofilm assays were performed with plastic microtiter plates and medical device substrates (stainless-steel coupons and three catheter materials). The presence of nisin A significantly reduce the amount of biofilm formed on all surfaces. M17Q was significantly better at reducing biofilm production than nisin A on plastic and stainless-steel. Finally, M17Q was significantly better than nisin A at reducing bacterial numbers in a simulated wound fluid. The findings of this study suggest that nisin and bioengineered derivatives warrant further investigation as potential strategies for the control of S. epidermidis.en
dc.description.sponsorshipCork Institute of Technology (RÍSAM PhD Scholarship)en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid305en
dc.identifier.citationTwomey, E., Hill, C., Field, D. and Begley, M. (2020) ‘Bioengineered nisin derivative m17q has enhanced activity against staphylococcus epidermidis’, Antibiotics, 9(6), 305 (18pp). doi: 10.3390/antibiotics9060305en
dc.identifier.doi10.3390/antibiotics9060305en
dc.identifier.eissn2079-6382en
dc.identifier.endpage18en
dc.identifier.issued6en
dc.identifier.journaltitleAntibioticsen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/15710
dc.identifier.volume9en
dc.language.isoenen
dc.publisherMDPIen
dc.rights© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectBacteriocinen
dc.subjectAntibacterial peptideen
dc.subjectNisinen
dc.subjectBioengineered peptideen
dc.subjectStaphylococcus epidermidisen
dc.subjectMedical device related infectionsen
dc.subjectBiofilmen
dc.titleBioengineered nisin derivative m17q has enhanced activity against staphylococcus epidermidisen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
antibiotics-09-00305 (1).pdf
Size:
5.83 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Loading...
Thumbnail Image
Name:
antibiotics-09-00305-s001.pdf
Size:
614.94 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Materials
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description: